
The Lancet
@TheLancet
Followers
735K
Following
10K
Media
10K
Statuses
27K
Welcome to The Lancet, one of the world’s leading medical journals, published weekly since 1823.
London, New York, Beijing
Joined March 2009
On the cover, the Global Burden of Disease 2023 capstone examining the global burden of over 375 diseases, injuries, and risk factors in 204 countries and territories. Read this & more in our latest issue 👉 https://t.co/NmRGavu3ip
@IHME_UW #GBD
1
15
36
How can we improve health outcomes together? Join our webinar on Oct 23 to hear editors Mabel Chew, Zoë Mullan, & Pooja Jha discuss reporting race & ethnicity in research. Gain practical tips to apply to your research. 📆 Oct 23, 11am BST 👉 Register: https://t.co/MejBcIV1qC
0
3
3
Community-acquired pneumonia is the leading infectious cause of morbidity & mortality globally. Yet there are several challenges associated with diagnosis, treatment, & long-term management of Community-acquired pneumonia. Find out more in a new Seminar: https://t.co/4NsK4lDwOL
0
14
45
Presented at #ESMO25: "Zanzalintinib plus atezolizumab versus regorafenib in refractory colorectal cancer (STELLAR-303): a randomised, open-label, phase 3 trial"
thelancet.com
STELLAR-303 is the first phase 3 trial to show a significant improvement in overall survival with an immunotherapy-based regimen, zanzalintinib–atezolizumab, in patients with relapsed or refractory...
0
4
7
As injuries and deaths from motorcycle collisions soar, public health experts in Brazil are looking for solutions. @Lise_Alves reports from São Paulo: https://t.co/LN0KWvpXql
1
7
35
HARMONi-6: In patients with untreated advanced squamous NSCLC, ivonescimab plus chemotherapy showed significantly improved progression-free survival compared with tislelizumab plus chemotherapy, regardless of PD-L1 status. https://t.co/C6kHHPmbLa
#ESMO25
thelancet.com
In patients with untreated advanced squamous NSCLC, ivonescimab plus chemotherapy showed significantly improved progression-free survival compared with tislelizumab plus chemotherapy, regardless of...
3
15
45
A new study suggests iza-bren significantly improved the ORR compared with chemotherapy in individuals with heavily pretreated recurrent or metastatic nasopharyngeal carcinoma, with a manageable safety profile. https://t.co/u3ZwIyn5HE
#ESMO25
thelancet.com
Iza-bren significantly improved the ORR compared with chemotherapy in individuals with heavily pretreated recurrent or metastatic nasopharyngeal carcinoma, with a manageable safety profile. These...
2
10
32
Ultra-processed foods are reshaping global diets, health, & the planet. Join us for the global launch of a new Series on UPFs & Human Health on 19 Nov. 🌍 Experts will unpack the science, policy, & politics of #UPFs. Register 👉 https://t.co/JRJDGKtQZ0
3
37
96
In patients with resectable hepatocellular carcinoma at intermediate or high risk of recurrence, perioperative camrelizumab plus rivoceranib significantly improved event-free survival compared with surgery alone, suggests new study. https://t.co/nqjSrRx1vm
#ESMO25
4
15
36
“There are endless possibilities” Talha Burki speaks with Fred Ramsdell, Mary Brunkow, and Shimon Sakaguchi about their Nobel-winning discoveries in peripheral immune tolerance:
thelancet.com
Talha Burki speaks with Fred Ramsdell, Mary Brunkow, and Shimon Sakaguchi about their Nobel-winning discoveries in peripheral immune tolerance.
1
11
47
Register now! 📣 Join us for the launch of the 2025 Global Report of the @LancetCountdown. 🗓️ 29 Oct | 14:00–16:00 GMT 🎙️ With @HelenClarkNZ, @JuliaGillard, @DrTedros & more 📊 Latest climate & health data, plus insights from global experts 🔗 https://t.co/Jh0yz2h7LV
2
9
27
Are we adequately preparing for future health crises? In a new Offline, Richard Horton explores how scenario planning can shape resilient health policies and ensure justice for health worldwide:
thelancet.com
Cesar Victora delivered a terrific Pumphandle Lecture at the London School of Hygiene & Tropical Medicine last week. He surveyed 40 years of his research on child health and nutrition in Pelotas,...
3
8
23
“These papers lay out for the first time a comprehensive description of health in the post-pandemic world.” 📄 A Lancet Editorial provides an overview of 3 new articles, presented at the @WorldHealthSmt: https://t.co/6u6VxB75TH
#WHS2025 #GDBStudy @IHME_UW
thelancet.com
The COVID-19 pandemic upended global mortality and morbidity. COVID-19 was ranked as the number one age-standardised cause of death globally in 2021 but by 2023 had dropped to the 20th cause of death...
12
21
48
📢 Have you registered yet? Enhance your research impact with expert guidance from Lancet Group editors. Learn how SAGER guidelines for sex- and gender-based analyses can strengthen your work, with real examples and actionable insights. 👉 Register: https://t.co/A9yKLwcq5B
0
8
37
The results of #POTOMAC trial are out in @TheLancet simultaneously released with #ESMO25 presentation @myESMO Happy to share our thoughts on this also out in the accompanying editorial. @SanRaffaeleMI @MyUniSR Front-line durvalumab and BCG in the treatment of
1
29
76
Read the linked Comment: “Front-line durvalumab and BCG in the treatment of non-muscle-invasive bladder cancer” ⤵️
thelancet.com
Over the past 5 years, systemic therapy for urothelial carcinoma has changed considerably throughout the clinical stages.1 In addition to regulatory approvals of immune-checkpoint inhibitor (ICI)-b...
0
0
1
In patients with BCG-naive, high-risk non-muscle-invasive bladder cancer, 1 year of durvalumab with BCG induction & maintenance therapy showed a statistically significant, clinically meaningful improvement in disease-free survival vs BCG induction & maintenance alone.
4
14
39
NEW ISSUE: Read the latest content on central retinal artery occlusion, stroke risk in women, Alzheimer's disease, unruptured intracranial aneurysms, Parkinson's disease, and more at: https://t.co/uHBDsIJpFa
3
12
41
The world produces enough food, yet billions lack access to healthy & sustainable diets. A new @EatForum–Lancet report presents a science-based approach to improve health, safeguard our environment & provide for a projected 9.6 billion people by 2050. 🔗 https://t.co/gowTyhFhzo
3
15
41